checkAd

Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model

Nachrichtenquelle: globenewswire
01.04.2021, 14:00  |  255   |  19   |   

Highlights:

  • Positive sinusitis infection data indicated in animal study
  • Study supports broad spectrum potential of Recce’s anti-infective compounds against Streptococcus pneumoniae (S. pneumoniae) for both nasal and intravenous administration
  • RECCE 327 (R327) and experimental RECCE 111 (R111) tested against marketed therapeutic alternative in-vivo in sinusitis study; independent study agreement anticipated

SYDNEY, Australia, April 01, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Company), the Company developing New Classes of Synthetic Anti-Infectives, is pleased to announce animal study data showing positive efficacy of a new anti-infective formulation RECCE 111 (R111) against Streptococcus pneumoniae (S. pneumoniae) bacterial sinusitis in mice. RECCE 111 is a non-descript title for an experimental compound, developed in-house, building upon the unique mechanisms of action of RECCE 327.

“We’re continually excited by the potential of Recce’s anti-infective compounds and are encouraged by these positive indications,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Moreover, this further enhances the breadth of Recce’s synthetic polymer platform.”

The study was conducted by an independent Contract Research Organization, to assess the dose-dependency of R327 and R1111 in-vivo antibacterial activity against S. pneumoniae in a mouse model of acute bacterial rhinosinusitis infection.

Efficacy of Recce Anti-infectives in Acute Bacterial Rhinosinusitis Treatment Table
Group Treatment Clinical Observation
1 Early infection control (day1 post infection) NAD
2 Infection vehicle control, twice daily, oral, 5 days NAD
3 Positive Control (Azithromycin, oral, 200 mg/kg, twice daily, 5 days) NAD
4 RECCE 327 (Low dose, Nasal, 50 mg/kg, Twice daily, 5 days) NAD
5 RECCE 327 (Mid dose, Nasal, 100 mg/kg, Twice daily, 5 days) NAD
6 RECCE 327 (High dose, Nasal, 500 mg/kg, Twice daily, 5 days) NAD
7 RECCE 327 (Low dose, IV, 100 mg/kg, Twice daily, 5 days) NAD
8 RECCE 327 (Mid dose, IV, 500 mg/kg, Twice daily, 5 days) NAD
9 RECCE 327 (High dose, IV, 1000 mg/kg, Twice daily, 5 days) NAD
10 RECCE 111 (Low dose, IV, 50 mg/kg, Twice daily, 5 days) NAD
11 RECCE 111 (Mid dose, IV, 100 mg/kg, Twice daily, 5 days) NAD
12 RECCE 111 (High dose, IV, 250 mg/kg, Twice daily, 5 days) NAD
Efficacy Acute Bacterial Rhinosinusitis
Seite 1 von 3
Recce Pharmaceuticals Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





19 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Kommentare

Avatar
06.05.21 11:37:07
Hier müssen wir ein bisschen Stehvermögen mitbringen. Wenn die Wirkung so wie beschrieben ist und sich bestätigt, dann werden wir mit dieser Aktie noch viel Freude haben. Auf sowas artet die Welt!:rolleyes:
Avatar
05.05.21 09:36:46
Gestriger SK von $1.195 heute morgen bestätigt.
Avatar
04.05.21 18:30:16


great video with CEO
Avatar
04.05.21 16:51:33
this company will surge in value in next few months as large institutions buy in.....
Avatar
04.05.21 14:55:46
"Mehr als 99,9% wirksam gegen eine vollständige Reihe von ESKAPE-Pathogenen innerhalb von Stunden nach Exposition gegenüber RECCE 327 (R327) in unabhängigen bakteriellen Wirksamkeitsstudien"

Disclaimer

Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model Highlights: Positive sinusitis infection data indicated in animal study Study supports broad spectrum potential of Recce’s anti-infective compounds against Streptococcus pneumoniae (S. pneumoniae) for both nasal and intravenous administration RECCE …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel